Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bicycle Therapeutics stock

Learn how to easily invest in Bicycle Therapeutics stock.

Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 119 staff and has a trailing 12-month revenue of around $15 million.

How to buy Bicycle Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – BCYC. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Bicycle Therapeutics stock price (NASDAQ: BCYC)

Use our graph to track the performance of BCYC stocks over time.

Bicycle Therapeutics shares at a glance

Information last updated 2023-01-19.
Latest market close$27.96
52-week range$12.08 - $51.93
50-day moving average $29.08
200-day moving average $24.21
Wall St. target price$53.64
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.91

Buy Bicycle Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Bicycle Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bicycle Therapeutics price performance over time

Historical closes compared with the close of $27.96 from 2023-01-25

1 week (2023-01-20) 1.82%
1 month (2022-12-27) -1.27%
3 months (2022-10-27) 16.50%
6 months (2022-07-27) 14.83%
1 year (2022-01-27) -39.64%
2 years (2021-01-27) 8.92%
3 years (2020-01-27) 151.89%
5 years (2018-01-23) N/A

Bicycle Therapeutics financials

Revenue TTM $15 million
Gross profit TTM $-33,183,000
Return on assets TTM -18.34%
Return on equity TTM -43.79%
Profit margin 0%
Book value $9.75
Market capitalisation $816.5 million

TTM: trailing 12 months

Bicycle Therapeutics share dividends

We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.

Bicycle Therapeutics share price volatility

Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $12.08 up to $51.932. A popular way to gauge a stock's volatility is its "beta".

BCYC.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.7746. This would suggest that Bicycle Therapeutics's shares are less volatile than average (for this exchange).

Bicycle Therapeutics overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

What percentage of Bicycle Therapeutics is owned by insiders or institutions?
Currently 9.978% of Bicycle Therapeutics shares are held by insiders and 91.668% by institutions.
How many people work for Bicycle Therapeutics?
Latest data suggests 119 work at Bicycle Therapeutics.
When does the fiscal year end for Bicycle Therapeutics?
Bicycle Therapeutics's fiscal year ends in December.
Where is Bicycle Therapeutics based?
Bicycle Therapeutics's address is: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT
What is Bicycle Therapeutics's ISIN number?
Bicycle Therapeutics's international securities identification number is: US0887861088
What is Bicycle Therapeutics's CUSIP number?
Bicycle Therapeutics's Committee on Uniform Securities Identification Procedures number is: 088786108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site